New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:35 EDTINFI, GILDGilead study 'alarming,' says Stifel
Stifel believes that a study of Gilead's (GILD) GS-9973+idelalisib - which it says terminated early due to the development of severe pneumonitis in nine patients - is "alarming." The firm adds that Gilead's results may prevent Infinity Pharmaceuticals (INFI) - which the firm thinks has plans to combine IPI-145 with a Btk inhibitor - from finding future commercial partners. However, it keeps Buy ratings on both Gilead and Infinity.
News For GILD;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
16:00 EDTGILDOptions Update; March 5, 2015
Subscribe for More Information
13:01 EDTINFINomura sees more M&A following AbbVie's acquisition of Pharmacyclics
Nomura believes AbbVie's (ABBV) acquisition of Pharmacyclics (PCYC) supports its call that Receptos (RCPT) and Infinity Pharmaceuticals (ICPT) are on the top of M&A lists given both companies have potential $5B in peaks sales potential and unencumbered assets. Additionally, the firm believes the deal has positive implications for Neutral rated Incyte (INFI) given the potential AbbVie can now evaluate ABT-199 in combination with Incyte's duvelisib and Pharmacyclic's Imbruviea across a range of hematological malignancies.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
March 4, 2015
11:09 EDTGILDSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
March 3, 2015
07:08 EDTGILDAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
March 2, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
February 27, 2015
07:37 EDTGILDGilead removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 26, 2015
19:09 EDTGILDGilead announces Phase 3 results for once-daily single tablet HIV regimen
Gilead Sciences announced detailed 48-week results from two Phase 3 studies, Studies 104 and 111, evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide, or TAF, for the treatment of HIV-1 infection in treatment-naÔve adults. A regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg was found to be statistically non-inferior to Gileadís Stribild, containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. A second analysis found that patients receiving the TAF regimen also had significantly better renal and bone laboratory parameters than those treated with Stribild. The data were presented in two late-breaker presentations at the 22nd Conference on Retroviruses and Opportunistic Infections in Seattle.
15:25 EDTGILDGilead announces 96% SVR12 rate in Phase 3 study of Harvoni
Subscribe for More Information
February 25, 2015
15:30 EDTGILDGilead announces preclincal data on investigational TLR7 agonist
Subscribe for More Information
February 24, 2015
16:04 EDTINFIInfinity Pharmaceuticals reports Q4 EPS (83c), consensus (98c)
Reports Q4 revenue $4.36M, consensus $5.61M. Completion of patient enrollment in DYNAMO and DUO trials expected in 2015, topline data from DYNAMO is anticipated in the second half of 2015 and three new clinical studies of Duvelisib are expected to begin in 2015, the company said. At December 31, 2014, Infinity had total cash, cash equivalents and available-for-sale securities of $333.2M, compared to $214.5M at December 31, 2013.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
February 23, 2015
16:00 EDTGILDOptions Update; February 23, 2015
Subscribe for More Information
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use